Sticking Points in Compounding Talks Reflect Long-Held FDA Frustrations--

Drug Industry Daily Sept. 17, 2013  | Vol. 12 No. 181   House and Senate aides negotiating compounding pharmacy legislation are quibbling over what volume of interstate commerce by compounders should trigger mandatory FDA oversight, and how that volume should be measured. This article is viewable by subscribers only. To view this article, please select an option below.